A type III effector protease NleC from enteropathogenic Escherichia coli targets NF-κB for degradation
2011

NleC: A Bacterial Effector That Degrades NF-κB

publication 10 minutes Evidence: moderate

Author Information

Author(s): Jaclyn S. Pearson, Patrice Riedmaier, Olivier Marchès, Gad Frankel, Elizabeth L. Hartland

Primary Institution: University of Melbourne

Hypothesis

Can NleC from enteropathogenic Escherichia coli inhibit NF-κB activation?

Conclusion

NleC is a type III effector protease that degrades NF-κB, contributing to the inhibition of innate immune activation.

Supporting Evidence

  • NleC was shown to induce degradation of the NF-κB subunit p65.
  • NleC inhibited IL-8 production during prolonged EPEC infection.
  • A double nleE/nleC mutant was more impaired in inhibiting IL-8 secretion than single mutants.

Takeaway

NleC is like a tiny ninja that sneaks into cells and breaks down a part of the immune system called NF-κB, helping bacteria avoid being attacked.

Methodology

The study involved screening T3SS effectors for their ability to inhibit p65 nuclear translocation and assessing their effects on IL-8 secretion.

Limitations

The study primarily focused on in vitro experiments, which may not fully represent in vivo conditions.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1111/j.1365-2958.2011.07568.x

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication